The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

People with bipolar I disorder have had at least one manic episode preceded or followed by hypomanic or major depressive ...

Neurocrine Biosciences begins phase 3 registrational study of osavampator as an adjunctive therapy to treat major depressive disorder: San Diego Wednesday, January 29, 2025, 18:00 ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...